Oxana Denisova receives 30 000 grant from Aamu foundation for her research on ‘PP2A in medulloblastoma therapy resistance: novel opportunities for targeted therapeutics.’

– My current research interest belongs to a field of brain cancer resistance and anticancer therapy development, particularly I focus on a role of protein phosphatase 2A (PP2A) and its inhibitor proteins in glioblastoma and pediatric medulloblastoma. I recently demonstrated that combination of PP2A reactivation and multi-kinase inhibition results in profound synergistic cell killing of adult glioblastoma and medulloblastoma cells, Oxana tells.